
On Thursday, shares in Novavax increased by 13.5% in value, while its larger competitor Moderna reached the upper echelons of the S&P 500 index after a 7.9% value increase.
It was a good day for the vaccine producers as investors can spot new growth on the horizon, as more and more countries prepare to vaccinate their populations with updated vaccines targeting the Omicron variant of Covid-19.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app